Back to search

Article

Generation of frameshift mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV- 1/GM-CSF in a Phase 1 study

2024-12-19

Abstract excerpt

<title>Abstract</title> <p>FMPV-1 is a component of FMPV-3, an investigational cancer-specific vaccine and being developed to activate anti-cancer T-cell responses targeting frameshift mutations of MSI-H cancers. FMPV-1 is designed to activate T-cell responses against transforming growth factor β receptor 2 (TGFβR2) frameshift mutation. Microsatellite instability High (MSI-H) gastrointestinal cancers frequently h...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
088a7b27-3e12-5b3c-b8b2-b500b07ca3cd
DOI
10.21203/rs.3.rs-5418259/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Generation of frameshift mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV- 1/GM-CSF in a Phase 1 studyDOI 10.21203/rs.3.rs-5418259/v2
Heat-inactivated modified vaccinia virus Ankara boosts Th1-biased cellular and humoral immune responses as a vaccine adjuvant by activating the STING-mediated cytosolic DNA-sensing pathwaySemantic proximity
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesSemantic proximity
Development of an in vitro method to assess the immunogenicity of biologics in the prevention of infectious diseasesSemantic proximity
Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated VacciniaSemantic proximity
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung CancerSemantic proximity
Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersSemantic proximity
Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination.Semantic proximity
Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosineSemantic proximity
DNA Immunotherapy for Recurrent Respiratory Papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107Semantic proximity
Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer ImmunotherapySemantic proximity
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 TrialSemantic proximity
Tr1 cell-mediated protection against autoimmune disease by intranasal administration of a fusion protein targeting cDC1 cellsSemantic proximity
Select a neighboring publication to make it the new centre.